High telomerase activity bone marrow mesenchymal stem cells, methods of producing the same and pharmaceuticals and treatment methods based thereon

Abstract

Disclosed are isolated human bone marrow mesenchymal stem cells having high telomerase activity (tBMMSCs). Also disclosed are isolated human CD34 + bone marrow mesenchymal stem cells. Also disclosed are bone marrow mesenchymal stem cells treated with a telomerase induction agent.

We claim: 
     
         1 . A method of modulating immune system of a human patient comprising administering to the patient a therapeutically effective amount of isolated high telomerase human bone marrow mesenchymal stem cells. 
     
     
         2 . The method of  claim 1 , wherein the isolated high telomerase human bone marrow mesenchymal stem cells are prepared by treating human bone marrow mesenchymal stem cells with an effective amount of telomerase inducing agent. 
     
     
         3 . The method of  claim 2 , wherein the telomerase inducing agent comprises aspirin or a compound with similar chemical structure. 
     
     
         4 . The method of  claim 2 , wherein the telomerase inducing agent comprises aspirin. 
     
     
         5 . The method of  claim 4 , wherein amount of aspirin used in the treatment of human bone marrow mesenchymal stem cells is in the range of 2 micrograms/milliliter to 50 micrograms/milliliter. 
     
     
         6 . The method of  claim 5 , wherein the human bone marrow mesenchymal stem cells are treated with aspirin for about one week. 
     
     
         7 . The method of  claim 2 , wherein the human bone marrow mesenchymal stem cells are treated with an effective amount of telomerase inducing agent ex-vivo. 
     
     
         8 . The method of  claim 1 , wherein the patient has an immune disorder. 
     
     
         9 . The method of  claim 1 , wherein the patient has systemic lupus erythematosus.